Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Strasser

Showing results (321-330 of 369) with videos related to

Pageof 37
Sort By:
Molecular and Cellular Biochemistry|December 7, 2007
Chelerythrine treatment influences the balance of pro- and anti-apoptotic signaling pathways in the remote myocardium after infarctionGregor Simonis, Stephan Wiedemann, Kerstin Schwarz, et al.
Basic Research in Cardiology|June 8, 2013
Impact of Hey2 and COUP-TFII on genes involved in arteriovenous differentiation in primary human arterial and venous endothelial cellsSlobodanka Korten, Coy Brunssen, David M Poitz, et al.
Biochemical and Biophysical Research Communications|October 28, 2008
Nitric oxide synthases are crucially involved in the development of the severe cardiomyopathy of caveolin-1 knockout miceCarsten Wunderlich, Kristin Schober, Michael Kasper, et al.
Patterns (New York, N.Y.)|August 25, 2020
Transitive Sequencing Medical Records for Mining Predictive and Interpretable Temporal RepresentationsHossein Estiri, Zachary H Strasser, Jeffery G Klann, et al.
The Canadian Journal of Cardiology|November 28, 2017
Endothelial Nitric Oxide Synthase-Induced Hypertrophy and Vascular Dysfunction Contribute to the Left Ventricular Dysfunction in Caveolin-1<sup>-/-</sup> MiceAnnette Ebner, Nadine Kuerbis, Aljoscha Brandt, et al.
Journal of Cardiovascular Pharmacology|March 12, 2013
Dexrazoxane prevents the development of the impaired cardiac phenotype in caveolin-1-disrupted miceAnne-Katrin Polanski, Annette Ebner, Bernd Ebner, et al.
Atherosclerosis|February 25, 2014
Local inhibition of hypoxia-inducible factor reduces neointima formation after arterial injury in ApoE-/- miceMarian Christoph, Karim Ibrahim, Kathleen Hesse, et al.
Cardiology|May 14, 2015
Effects of the Peroxisome Proliferator-Activated Receptor-γ Agonist Pioglitazone on Peripheral Vessel Function and Clinical Parameters in Nondiabetic Patients: A Double-Center, Randomized Controlled Pilot TrialMarian Christoph, Joerg Herold, Anna Berg-Holldack, et al.
JAMA Network Open|May 29, 2025
Dedicated AI Expert System vs Generative AI With Large Language Model for Clinical DiagnosesMitchell J Feldman, Edward P Hoffer, Jared J Conley, et al.
Journal of Molecular and Cellular Cardiology|April 18, 2008
The adverse cardiopulmonary phenotype of caveolin-1 deficient mice is mediated by a dysfunctional endotheliumCarsten Wunderlich, Kristin Schober, Alexander Schmeisser, et al.
Pageof 37

Showing results (321-330 of 369) with videos related to

Sort By:
Pageof 37
Molecular and Cellular Biochemistry|December 7, 2007
Chelerythrine treatment influences the balance of pro- and anti-apoptotic signaling pathways in the remote myocardium after infarctionGregor Simonis, Stephan Wiedemann, Kerstin Schwarz, et al.
Basic Research in Cardiology|June 8, 2013
Impact of Hey2 and COUP-TFII on genes involved in arteriovenous differentiation in primary human arterial and venous endothelial cellsSlobodanka Korten, Coy Brunssen, David M Poitz, et al.
Biochemical and Biophysical Research Communications|October 28, 2008
Nitric oxide synthases are crucially involved in the development of the severe cardiomyopathy of caveolin-1 knockout miceCarsten Wunderlich, Kristin Schober, Michael Kasper, et al.
Patterns (New York, N.Y.)|August 25, 2020
Transitive Sequencing Medical Records for Mining Predictive and Interpretable Temporal RepresentationsHossein Estiri, Zachary H Strasser, Jeffery G Klann, et al.
The Canadian Journal of Cardiology|November 28, 2017
Endothelial Nitric Oxide Synthase-Induced Hypertrophy and Vascular Dysfunction Contribute to the Left Ventricular Dysfunction in Caveolin-1<sup>-/-</sup> MiceAnnette Ebner, Nadine Kuerbis, Aljoscha Brandt, et al.
Journal of Cardiovascular Pharmacology|March 12, 2013
Dexrazoxane prevents the development of the impaired cardiac phenotype in caveolin-1-disrupted miceAnne-Katrin Polanski, Annette Ebner, Bernd Ebner, et al.
Atherosclerosis|February 25, 2014
Local inhibition of hypoxia-inducible factor reduces neointima formation after arterial injury in ApoE-/- miceMarian Christoph, Karim Ibrahim, Kathleen Hesse, et al.
Cardiology|May 14, 2015
Effects of the Peroxisome Proliferator-Activated Receptor-γ Agonist Pioglitazone on Peripheral Vessel Function and Clinical Parameters in Nondiabetic Patients: A Double-Center, Randomized Controlled Pilot TrialMarian Christoph, Joerg Herold, Anna Berg-Holldack, et al.
JAMA Network Open|May 29, 2025
Dedicated AI Expert System vs Generative AI With Large Language Model for Clinical DiagnosesMitchell J Feldman, Edward P Hoffer, Jared J Conley, et al.
Journal of Molecular and Cellular Cardiology|April 18, 2008
The adverse cardiopulmonary phenotype of caveolin-1 deficient mice is mediated by a dysfunctional endotheliumCarsten Wunderlich, Kristin Schober, Alexander Schmeisser, et al.
Pageof 37